Enzyme finance is appealing to fund managers and possibly to institutional investors.
I think it would be beneficial to both platform if SmartYield was available on Enzyme.
Compound and Aave are part of their investment assets so I am convinced the investors would be interested in SmartYield.
Their TVL is still small but they are growing quite fast. A good thing is that Mona El Isa (C-founder) has a background in traditional finance so she certainly has some contacts in that industry.